Aktieanalys

Vitrolife Q4: Genetic Services improves gradually - Redeye

Redeye Publicerad: 02 Feb 09:20

As a result of the earlier trading update, the main interest is in the outlook, especially for the US-related Genetic Services business. The EMEA region delivers balanced improvements, and the APAC continues to deliver very solid growth whilst the US continues to be exposed to pressure from mainly the ERA-related business. We note that Vitrolife delivered a strong gross margin in Q4 despite a surprisingly strong quarter in the Technologies business. Our Base Case ahead of Q4 is SEK 235 (Bull SEK 375 and Bear SEK 85).

Länk till analysen i sin helhet: https://www.redeye.se/research/974273/vitrolife-q4-genetic-services-improves-gradually?utm_source=finwire&utm_medium=RSS

Nyheter om Vitrolife

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!